|Positive WB detected in||mouse brain tissue, human brain tissue, rat brain tissue|
|Positive IF detected in||HeLa cells|
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
The immunogen of 24072-1-AP is Rac1 Fusion Protein expressed in E. coli.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||hamster, human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Rac1 fusion protein Ag17779|
|Full Name||ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)|
|Calculated molecular weight||21 kDa|
|Observed molecular weight||21 kDa|
|GenBank accession number||BC004247|
|Gene ID (NCBI)||5879|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
RAC1b, also named as TC25, belongs to the small GTPase superfamily and Rho family. RAC1 is a plasma membrane-associated small GTPase which cycles between active GTP-bound and inactive GDP-bound states. In its active state, it binds to a variety of effector proteins to regulate cellular responses such as secretory processes, phagocytosis of apoptotic cells, epithelial cell polarization and growth-factor induced formation of membrane ruffles.
Pharmacol Biochem Behav
Protective effects of ginsenoside Rg1 on chronic restraint stress induced learning and memory impairments in male mice.
Int J Mol Med
PEDF improves cardiac function in rats subjected to myocardial ischemia/reperfusion injury by inhibiting ROS generation via PEDF‑R.
CSTF2-induced shortening of the RAC1 3'UTR promotes the pathogenesis of urothelial carcinoma of the bladder.
Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network.
Modulation of the Pol II CTD Phosphorylation Code by Rac1 and Cdc42 Small GTPases in Cultured Human Cancer Cells and Its Implication for Developing a Synthetic-Lethal Cancer Therapy.
J Exp Clin Cancer Res
TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1.